ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

BHE Q3 Deep Dive: Sector Diversification and Bookings Momentum Support Outlook

BHE Cover Image

Electronics manufacturing services provider Benchmark (NYSE: BHE) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 3.5% year on year to $680.7 million. The company expects next quarter’s revenue to be around $695 million, close to analysts’ estimates. Its non-GAAP profit of $0.62 per share was 8.1% above analysts’ consensus estimates.

Is now the time to buy BHE? Find out in our full research report (it’s free for active Edge members).

Benchmark (BHE) Q3 CY2025 Highlights:

  • Revenue: $680.7 million vs analyst estimates of $661.7 million (3.5% year-on-year growth, 2.9% beat)
  • Adjusted EPS: $0.62 vs analyst estimates of $0.57 (8.1% beat)
  • Adjusted EBITDA: $35.51 million (5.2% margin, 16% year-on-year decline)
  • Revenue Guidance for Q4 CY2025 is $695 million at the midpoint, roughly in line with what analysts were expecting
  • Adjusted EPS guidance for Q4 CY2025 is $0.65 at the midpoint, roughly in line with what analysts were expecting
  • Operating Margin: 3.5%, in line with the same quarter last year
  • Market Capitalization: $1.54 billion

StockStory’s Take

Benchmark’s third quarter performance was met with a positive market response, supported by broad-based sector contributions and strong execution on new program wins. Management highlighted double-digit growth in both medical and aerospace & defense (A&D), while industrial and advanced computing & communications (AC&C) also posted sequential gains. CEO Jeffrey Benck noted, “I was particularly encouraged by the broadening of sectors that contributed to our revenue growth,” and pointed to a multiyear record in cash cycle efficiency, reflecting disciplined working capital management. Supply chain normalization in the medical segment and new product ramps provided additional lift, offsetting some softness in semi-cap equipment due to external trade restrictions and cyclical headwinds.

Looking ahead, Benchmark’s guidance is underpinned by continued strength in its medical, A&D, and industrial sectors, alongside emerging opportunities in AI-related advanced computing. President David Moezidis referenced new engineering wins in medtech and emphasized that “AI wins are starting to ramp in Q4 and into 2026, coupled with HPC builds over the coming quarters.” While management acknowledged ongoing challenges in semi-cap from tariffs and demand timing, they expressed confidence in sequential and year-over-year growth, supported by a growing pipeline and strategic investments in capacity, particularly in Penang, Malaysia. Management also highlighted their expectation for incremental growth in 2026 to drive operating leverage and earnings expansion.

Key Insights from Management’s Remarks

Management attributed quarterly performance to diversified sector growth, disciplined working capital management, and new program bookings, while highlighting sector-specific challenges and opportunities.

  • Medical segment recovery: The medical sector experienced both sequential and year-over-year growth as customer inventory levels normalized and new product ramps gained momentum. Management credited engineering wins in medtech as a key entry point for future manufacturing business.
  • Aerospace & defense momentum: Double-digit revenue growth in A&D was driven by strong defense demand, particularly in Europe and the Americas, as well as accelerating bookings in the satellite and space subsectors. President David Moezidis noted recent substantial manufacturing wins in space communications.
  • Industrial sector stability: The industrial business returned to year-over-year growth, aided by new wins in transportation and surveillance. Management sees industrial as a significant future growth engine, citing ongoing expansion of the customer base and design contracts.
  • AC&C AI-driven outlook: AC&C saw improved visibility into growth, with management pointing to AI and high-performance computing (HPC) wins that are expected to ramp into late 2025 and 2026. CEO Jeffrey Benck described Benchmark’s focus on sovereign and enterprise AI opportunities over hyperscale cloud providers.
  • Semi-cap headwinds and investments: Semi-cap revenue was flat, with management citing near-term demand challenges from China restrictions and tariffs. However, continued investments in precision machining—especially in Malaysia—position Benchmark to capture share as the sector recovers, with customers signaling optimism for a second-half 2026 upturn.

Drivers of Future Performance

Management expects future performance to be shaped by sector diversification, new technology adoption, and ongoing investments in capacity and automation.

  • AI and HPC program ramps: Benchmark anticipates that recently secured AI and high-performance computing contracts in AC&C will drive incremental revenue growth, especially as buildouts for government and enterprise customers accelerate throughout 2026. Management highlighted that their water-cooled infrastructure supports these projects and enables participation in sovereign and enterprise AI opportunities.
  • Medical and industrial sector growth: The company expects medical and industrial segments to deliver continued sequential and year-over-year growth, supported by normalized channel inventories and new customer wins. Management views medtech engineering contracts and transportation-related programs as sources of ongoing upside.
  • Cyclical semi-cap recovery: While near-term demand in semi-cap remains mixed due to external trade factors, management is cautiously optimistic that customer activity will pick up in the second half of 2026, citing positive signals from industry events and customer engagements. Investments in domestic and Malaysian capacity are designed to capture this expected rebound.

Catalysts in Upcoming Quarters

Looking forward, StockStory analysts will focus on (1) the pace of AI and HPC program ramp-ups in AC&C and whether early customer pilots convert to sustained production, (2) medical segment momentum as new engineering wins move into manufacturing, and (3) visibility into a semi-cap recovery, particularly the timing and magnitude of customer order growth. Additional signposts include progress on capacity expansion in Malaysia and any changes to defense or government spending trends.

Benchmark currently trades at $44.25, up from $43.01 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.

Don’t let fear keep you from great opportunities and take a look at Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.